Innovent Biologics and Jiangsu Aosaikang Pharmaceutical (ASK Pharm) have signed a strategic partnership agreement for the ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

We have gone through three generations of these TKIs. In the first generation were molecules like Erlotinib (Tarceva) and Gefitinib (Iressa), which were able to demonstrate high progression-free ...

Gefitinib and erlotinib are commonly used as salvage treatment of unselected patients with recurrent NSCLC after first-line chemotherapy. This practice is primarily based on the results from the ...

NICE said there is clinical trial evidence showing that Tagrisso stalls cancer growth longer than treatment with two older EGFR drugs, Roche’s Tarceva (erlotinib) and AZ’s Iressa (gefitinib).

Notable examples include imatinib for treating chronic myelogenous leukemia and gastrointestinal tumors, gefitinib and erlotinib for non-small-cell lung cancers, trastuzumab in women with breast ...

Giovenzio Genestreti; Francesco Grossi; Carlo Genova; Marco A Burgio; Alberto Bongiovanni; Giampaolo Gavelli; Marco Bartolotti; Monica Di Battista; Giovanna Cavallo; Alba A Brandes S-1 is an oral ...

The company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab) ...

While there he was responsible for the biology of the project that produced the EGFR kinase inhibitor gefitinib (Iressa) that has received regulatory approval in non small cell lung cancer and was one ...

AstraZeneca’s TAGRISSO® (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung ...

In a multi-center, randomized, double-blind, controlled Phase 3 clinical trial, limertinib's efficacy and safety were compared with gefitinib in the first-line treatment of patients with locally ...